17,833 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Acquired by Y Intercept Hong Kong Ltd

Key Points

• Y Intercept Hong Kong Ltd acquired 17,833 shares of Janux Therapeutics, valued at approximately $481,000, signaling increased institutional interest in the biotech company.
• Multiple hedge funds significantly increased their stakes in Janux Therapeutics during the 4th quarter, with Price T Rowe Associates Inc. raising their holdings by 596.3%.
• Janux Therapeutics reported an EPS of ($0.38) for its latest quarter, exceeding consensus estimates, and analysts estimate a target price of $91.89 for the stock.

Y Intercept Hong Kong Ltd acquired a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 17,833 shares of the company's stock, valued at approximately $481,000.

Other institutional investors also recently bought and sold shares of the company. RA Capital Management L.P. grew its stake in Janux Therapeutics by 13.1% in the 4th quarter. RA Capital Management L.P. now owns 10,365,652 shares of the company's stock valued at $554,977,000 after acquiring an additional 1,200,000 shares during the last quarter. FMR LLC grew its stake in Janux Therapeutics by 10.8% in the 4th quarter. FMR LLC now owns 8,669,941 shares of the company's stock valued at $464,189,000 after acquiring an additional 845,266 shares during the last quarter. Janus Henderson Group PLC boosted its stake in shares of Janux Therapeutics by 41.2% during the 4th quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company's stock worth $190,617,000 after purchasing an additional 1,038,996 shares during the last quarter. Paradigm Biocapital Advisors LP boosted its stake in shares of Janux Therapeutics by 46.5% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company's stock worth $188,246,000 after purchasing an additional 1,115,412 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its stake in shares of Janux Therapeutics by 47.6% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company's stock worth $163,926,000 after purchasing an additional 986,750 shares during the last quarter. 75.39% of the stock is owned by institutional investors and hedge funds.

Janux Therapeutics Stock Performance

Shares of Janux Therapeutics stock traded down $0.27 on Thursday, hitting $23.96. The company's stock had a trading volume of 98,948 shares, compared to its average volume of 939,971. Janux Therapeutics, Inc. has a 1 year low of $22.48 and a 1 year high of $71.71. The firm has a fifty day moving average price of $24.79 and a 200-day moving average price of $29.96. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of -17.61 and a beta of 2.86.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, topping analysts' consensus estimates of ($0.43) by $0.05. As a group, analysts forecast that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Raymond James Financial started coverage on shares of Janux Therapeutics in a report on Friday, July 11th. They issued an "outperform" rating and a $65.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $91.89.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.